Acurx Pharmaceuticals
ACXP
13 hedge funds and large institutions have $3.94M invested in Acurx Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
111% more capital invested
Capital invested by funds: $1.86M → $3.94M (+$2.07M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
8% more funds holding
Funds holding: 12 → 13 (+1)
0.4% more ownership
Funds ownership: 0.23% → 0.64% (+0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.69M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94K |
| 3 |
OGC
One68 Global Capital
New York
|
+$38.8K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$17.9K |
| 5 |
BlackRock
New York
|
+$8.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.2K |
| 2 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$10.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $3.13M | +$2.69M | +45,100 | +322% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $321K | +$94K | +1,578 | +35% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $205K | – | – | – |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $58.3K | +$17.9K | +300 | +38% |
|
|
5
BlackRock
New York
| $50K | +$8.1K | +136 | +17% |
|
|
TWC
6
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $49.4K | – | – | – |
|
|
7
Millennium Management
New York
| $45.9K | -$14.2K | -238 | -22% |
|
|
OGC
8
One68 Global Capital
New York
| $34.6K | +$38.8K | +652 | New |
|
|
TAM
9
Tocqueville Asset Management
New York
| $26.8K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $11.8K | +$4.59K | +77 | +53% |
|
|
SIC
11
Salem Investment Counselors
Winston Salem,
North Carolina
| $265 | +$298 | +5 | New |
|
12
Wells Fargo
San Francisco,
California
| $172 | – | – | – |
|
|
BAM
13
Belpointe Asset Management
Reno,
Nevada
| – | -$10.4K | -150 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$10K | -145 | Closed |
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$357 | +6 | New |
|
ACXP Hedge Fund Activity: Q2 2023 in Review
13 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q2 2023, worth a combined $3.94M — up 111% from $1.86M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ACXP positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $2.69M. The largest seller was Millennium Management, cutting an estimated $14.2K.
- 13 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q2 2023, up from 12 in Q1 2023.
- Funds reported $3.94M of Acurx Pharmaceuticals stock for Q2 2023, up 111% quarter-over-quarter.
- 3 funds opened new Acurx Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of +1 holder.
- The largest Acurx Pharmaceuticals buyer in Q2 2023 was Armistice Capital, an estimated $2.69M added.
- The largest Acurx Pharmaceuticals seller in Q2 2023 was Millennium Management, an estimated $14.2K sold.
Based on aggregated 13F filings for Q2 2023.